Julie Fradette
Chercheuse universitaire
Axe Médecine régénératrice
Publications
View all-
article Rioux Y, Fradette J, Hayward CJ, Séguin V, Maciel Y, Bégin-Drolet A, Ruel J
Innovative Sutureless Fabrication Strategy for Tissue-Engineered Pediatric Heart Valves Using an Evolutive Support System
Ann Biomed Eng 2026.
-
article Ricard-Blum S, Fradette J
An update on the landscape of collagen bioactive fragments
FEBS J 293 (13), 2026.
-
article Zhao J, Yu B, Fradette J, Annabi B, Petropavlovskaia M, Eliopoulos N
Preconditioning with StemRegenin 1 enhances human adipose stromal/stem cells proliferation, migration, and protection against antimycin A
Mol Ther Methods Clin Dev 33 (4), 2025.
Projects
- Engineering bioactive dressings from mesenchymal cells to enhance healing of irradiated skin wounds, from 2022-04-01 to 2027-03-31
- Skin Investigation Network of Canada (SkIN Canada), from 2020-01-01 to 2027-02-14
- GMEB-SASS: The first clinical trial phase I/II using a genetically modified epidermolysis bullosa self-assembled skin substitute to treat dystrophic epidermolysis bullosa, a severe rare skin disease, from 2024-04-01 to 2028-03-31
- Epidermolysis bullosa multidisciplinary team focusing on developing an effective cure for this severe rare skin disease, from 2025-03-01 to 2026-12-31
- Clinical trial for dystrophic epidermolysis bullosa (EB) using GMEB-SASS, a genetically modified EB skin substitute, from 2025-04-01 to 2028-03-31
- Toward a combined gene therapy and tissue engineering novel treatment for junctional epidermolysis bullosa, from 2025-04-01 to 2028-03-31
- Urethral reconstruction using tissue engineering, final steps towards clinical translation, from 2025-04-01 to 2030-03-31
- Roles of matricryptins (bioactive extracellular matrix fragments) in adipose tissue, from 2020-04-01 to 2026-03-31
- Développement de greffons d’épiderme autologue en combinant thérapie génique et génie tissulaire pour traiter l’épidermolyse bulleuse jonctionnelle, from 2024-04-01 to 2025-03-31
- Urethral reconstruction using tissue engineering, final steps towards clinical translation, from 2024-10-01 to 2025-03-31